human-derived microbes

C. diff. is an urgent public health issue

Prevention of recurrence may require restoration of the gut microbiome

Learn More

microbial product

Developing a new class of biologic drugs for the treatment of debilitating diseases

Learn More

healthy gut microbiota

Restoring the microbiome may provide therapies for challenging medical problems

New therapies beyond antibiotics are urgently needed

Learn More

Harnessing the Power of the Microbiome to Revolutionize Treatment of Disease

Rebiotix Inc. is a clinical stage biotechnology company founded to revolutionize the treatment of debilitating diseases by harnessing the power of the human microbiome.

It is increasingly recognized that restoration of a healthy gut microbiota is necessary for the effective treatment of a large number of challenging diseases.

The leader providing the Microbiota Restoration Therapy™ (MRT™) drug platform

The MRT platform is our science for delivering live, human-derived microbes into a sick patient’s intestinal tract to treat disease.

We have the most advanced human clinical program evaluating a microbiota-based drug conducted in coordination with a regulatory authority. Our current Phase 3 trial for the prevention of recurrent Clostridium difficile infection (PUNCH CD3) is currently enrolling – find out more about the trial, include eligibility criteria here.